| Today’s Big NewsMar 22, 2024 |
| By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. |
|
|
|
By Nick Paul Taylor Nkarta’s CAR NK blood cancer candidate has again stalled after making a speedy start. The response rate fell away sharply in the latest update, mirroring what happened in an earlier cohort and driving the cell therapy developer to mothball the program. |
By Gabrielle Masson After GSK’s $2 billion buyout of Canada-based Bellus Health last summer, an undisclosed number of the biotech’s team members are out of a job. |
By Annalee Armstrong Intellia Therapeutics is opting out of a hemophilia A/B program, leaving the CRISPR/Cas9-based gene editing work on factor IX treatments in the hands of partner Regeneron. |
By James Waldron Brii Biosciences is going on all in on hepatitis B, hoping that potential partners will show an interest in picking up a wide-ranging pipeline that includes HIV, lung disease and depression programs. |
By Gabrielle Masson,Max Bayer,Andrea Park Bayer’s pharmaceutical reinvention is continuing with a pair of new title additions for two members of the leadership team. |
By Ayla Ellison,James Waldron This week on “The Top Line,” we explore the European biotech investment landscape. Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. |
By Helen Floersh Johnson & Johnson Innovative Medicine and Trial Library, Inc. have expanded a partnership to integrate Trial Library’s clinical trial discovery platform into the pharmaceutical company’s oncology clinical development and medical affairs programs. |
By Fraiser Kansteiner At a watershed moment for Duchenne muscular dystrophy treatment, privately held Italian drugmaker Italfarmaco has added a new therapeutic option to the armamentarium against the debilitating muscle-wasting disorder. |
By Dave Muoio Providers spent nearly $20 billion in 2022 pursuing delays and denials across all payer types, yet those efforts are substantially more costly on average when dealing with private plans, hundreds of hospitals and health systems told Premier in a recent survey. |
By Angus Liu Three large pharma companies plan to expand their manufacturing footprints. Kyowa Kirin’s $4.25 million gene therapy set a new world pricing record. BeiGene’s PD-1 inhibitor finally crossed the FDA finish line after a 20-month delay. And more. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we explore the European biotech investment landscape. Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. |
|
|---|
|
|
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way,providing a robust and adaptable manufacturing platform for gene therapy breakthroughs. .png)
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
